Loading...
•
Dec 31, 2021
PTC Therapeutics Q4 2021 Earnings Report
PTC Therapeutics reported financial results for Q4 and full year 2021, with total revenues of $165.2 million for the quarter and $538.6 million for the year.
Key Takeaways
PTC Therapeutics announced Q4 and full year 2021 financial results, marked by a 41% year-over-year revenue growth. The company's total revenues for Q4 2021 reached $165.2 million, compared to $118.9 million in Q4 2020. Full year 2021 total revenues were $538.6 million, up from $380.8 million in 2020. The company reaffirmed its 2022 total revenue guidance of $700-750 million.
Total revenues for Q4 2021 were $165.2 million, compared to $118.9 million for Q4 2020.
Full year 2021 total revenues reached $538.6 million, a 41% increase year-over-year.
Translarna net product revenues were $69.7 million for Q4 2021, slightly up from $69.4 million in Q4 2020.
Emflaza net product revenues were $47.5 million for Q4 2021, compared to $36.8 million for Q4 2020.
Revenue by Segment
Forward Guidance
PTC reaffirmed its 2022 financial guidance, anticipating total revenues between $700 and $750 million and net product revenues for the DMD franchise between $475 and $495 million.
Positive Outlook
- Total revenues for the full year 2022 to be between $700 and $750 million.
- Net product revenues for the DMD franchise for the full year 2022 to be between $475 and $495 million.
- Results are expected mid-year for Translarna Study 041.
- Results are expected from the Phase 3 APHENITY trial of PTC923 in phenylketonuria (PKU) by the end of 2022.
- Opinion on marketing authorization application for PTC-AADC is expected in April 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...